Mesothelin SS-(dsFv)-PE38

Drug Profile

Mesothelin SS-(dsFv)-PE38

Alternative Names: Mesothelin Mab; Mesothelium Antigen Therapy - NeoPharm; SS(dsFv) PE38; SS1-PE38

Latest Information Update: 11 Nov 2004

Price : $50

At a glance

  • Originator Unknown
  • Developer National Cancer Institute (USA); NeoPharm Inc
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Head and neck cancer; Mesothelioma; Ovarian cancer

Most Recent Events

  • 31 Oct 2002 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 31 Oct 2002 Discontinued - Phase-II for Mesothelioma in USA (unspecified route)
  • 31 Oct 2002 Discontinued - Preclinical for Head and neck cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top